Sarepta Therapeutics 대차 대조표 상태
재무 상태 기준 확인 4/6
Sarepta Therapeutics 의 총 주주 지분은 $1.2B 이고 총 부채는 $1.2B, 이는 부채 대 자기자본 비율을 100.5% 로 가져옵니다. 총자산과 총부채는 각각 $3.6B 및 $2.4B 입니다. Sarepta Therapeutics 의 EBIT는 $81.0M 이며 이자보상배율은 -6.6 입니다. $1.2B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
100.5%
부채 비율
US$1.23b
부채
| 이자 보상 비율 | -6.6x |
| 현금 | US$1.20b |
| 주식 | US$1.22b |
| 총 부채 | US$2.38b |
| 총 자산 | US$3.60b |
최근 재무 상태 업데이트
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Recent updates
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 13Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20The Play On Sarepta Therapeutics
Sep 26Sarepta Therapeutics Muscles Up In DMD Race
Sep 19Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29재무 상태 분석
단기부채: SRPT 의 단기 자산 ( $2.7B )이 단기 부채( $699.5M ).
장기 부채: SRPT 의 단기 자산( $2.7B )이 장기 부채( $1.7B ).
부채 대 자본 내역 및 분석
부채 수준: SRPT 의 순부채 대 자기자본 비율( 2.4% )은 satisfactory로 간주됩니다.
부채 감소: SRPT 의 부채 대 자기자본 비율은 지난 5년간 43.9% 에서 100.5% 로 증가했습니다.
부채 범위: SRPT 의 영업현금흐름이 마이너스이므로 부채가 제대로 상환되지 않습니다.
이자 보장: SRPT 지불하는 것보다 더 많은 이자를 벌기 때문에 이자 지불 보장은 문제가 되지 않습니다.